Janux Therapeutics (JANX) vs Savara (SVRA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Savara (SVRA) has outperformed Janux Therapeutics (JANX) over the past year, gaining 39.2% versus a loss of 23.6%. Over five years, SVRA leads with a +274.4% price change compared with -12.4% for JANX. Janux Therapeutics is the larger company by market cap ($1.12 billion vs $1.01 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | JANX | SVRA |
|---|---|---|
| Share price | $18.39 | $4.92 |
| Market cap | $1.12B | $1.01B |
| 1-day change | -0.59% | +1.86% |
| YTD return | +34.06% | -19.90% |
| 1-year return | -23.55% | +39.19% |
| 5-year return | -12.45% | +274.42% |
| EPS (TTM) | $-1.64 | $-0.58 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $35.34 | $7.01 |
| 52-week low | $12.12 | $3.35 |
| Distance from 52-week high | -47.96% | -29.76% |
| Analyst consensus | none | none |
| Avg. price target upside | +97.06% | +124.80% |
| Average volume | 845.95K | 1.83M |
| Shares outstanding | 61.14M | 205.46M |
| Employees | 113 | 70 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SVRA has outperformed JANX by 62.7 percentage points over the past year.
About Janux Therapeutics
JANX stock →Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms technology to treat patients with cancer. The company's clinical candidates include JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor that is in Phase 1 clinical trial for the treatment of various solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, renal cell carcinoma, small cell lung cancer, pancreatic ductal adenocarcinoma, and triple-negative breast cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 113 employees
About Savara
SVRA stock →Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases in the United States. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis.
Health Care · Biotechnology: Pharmaceutical Preparations · 70 employees
JANX vs SVRA FAQ
Which is bigger, Janux Therapeutics or Savara?
Janux Therapeutics (JANX) is larger, with a market capitalization of $1.12B compared with $1.01B for Savara (SVRA).
Which stock has performed better over the past year, JANX or SVRA?
SVRA returned +39.19% over the past 12 months, compared with -23.55% for JANX (price return, excluding dividends). Past performance does not predict future results.
Are Janux Therapeutics and Savara in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.